Institutional members access full text with Ovid®

Share this article on:

Chronic Hepatitis C Virus Infection in Children

Mohan, Neelam*; González-Peralta, Regino P; Fujisawa, Tomoo; Chang, Mei-Hwei§; Heller, Solange||; Jara, Paloma; Kelly, Deirdre#; Mieli-Vergani, Giorgina**; Shah, Uzma††; Murray, Karen F‡‡

Journal of Pediatric Gastroenterology and Nutrition: February 2010 - Volume 50 - Issue 2 - p 123–131
doi: 10.1097/MPG.0b013e3181c61995
Invited Review

The importance of hepatitis C viral infection in the health care of children has grown in recent decades. More is now known about the epidemiology of this infection in children and the progression of disease in the pediatric age group, and the treatment options are increasing. In this review, we update readers on the state of our understanding of hepatitis C infection in children, provide the current recommendations for monitoring and treatment, and discuss emerging therapies.

*Department of Pediatrics, Centre of Child Health, Sir Ganga Ram Hospital, New Delhi, India

Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of Florida College of Medicine, Gainesville

Children's Center for Health and Development, Yokohama East Hospital, Yokohama City, Kanagawa, Japan

§Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan

||Gastroenterology and Nutrition Department, Hospital Infantil de México Federico Gómez, México, DF, Mexico

Pediatric University Hospital La Paz, Madrid, Spain

#Liver Unit, Birmingham Children's Hospital NHS Trust and University of Birmingham, Birmingham, UK

**Paediatric Liver Centre, King's College Hospital, London, UK

††Harvard Medical School Dubai Center, Dubai Health Care City, Dubai, UAE

‡‡Hepatobiliary Program, Seattle Children's, Seattle, WA.

Received 5 May, 2009

Accepted 15 September, 2009

Address correspondence and reprint requests to Karen F. Murray, MD, Director, Hepatobiliary Program, Seattle Children's, 4800 Sand Point Way, NE, PO Box 5371/W7830, Seattle, WA 98105 (e-mail:

Drs Murray and González-Peralta have received research funding from Roche.

The other authors report no conflicts of interest.

© 2010 Lippincott Williams & Wilkins, Inc.